European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Top Cited Papers
Open Access
- 1 October 2015
- journal article
- practice guideline
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 100 (10), 1254-1266
- https://doi.org/10.3324/haematol.2014.117176
Abstract
The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic lesions on conventional radiography can be treated with zoledronic acid (grade 1B), but its advantage is not clear for patients with no bone involvement on computed tomography or magnetic resonance imaging. In asymptomatic myeloma, bisphosphonates are not recommended (grade 1A). Zoledronic acid should be given continuously, but it is not clear if patients who achieve at least a very good partial response benefit from its continuous use (grade 1B). Treatment with erythropoietic-stimulating agents may be initiated in patients with persistent symptomatic anemia (hemoglobin streptococcus pneumonia and hemophilus influenza is appropriate, but efficacy is not guaranteed due to suboptimal immune response (grade 1C). Prophylactic aciclovir (or valacyclovir) is recommended for patients receiving proteasome inhibitors, autologous or allogeneic transplantation (grade 1A).Keywords
This publication has 100 references indexed in Scilit:
- Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for OutcomeClinical Lymphoma Myeloma and Leukemia, 2013
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica, 2013
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia, 2013
- Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling dataHaematologica, 2012
- The pathogenesis and diagnosis of acute kidney injury in multiple myelomaNature Reviews Nephrology, 2011
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialThe Lancet Oncology, 2011
- Vaccination of allogeneic haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHDVaccine, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working GroupJournal of Clinical Oncology, 2010
- Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEYEuropean Journal of Haematology, 2006